High Heated Humidity in Stem Cell Transplant

Last updated: January 28, 2025
Sponsor: AHS Cancer Control Alberta
Overall Status: Active - Recruiting

Phase

2

Condition

Stem Cell Transplant

Treatment

Airvo

Standard of Care

Clinical Study ID

NCT05358262
IIT-0017
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to find out what effects of high heated humidity has on you and your mucositis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Minimum 18 years of age

  2. Have given written consent prior to any study-specific procedures or have had anacceptable individual capable of giving consent on the patient's behalf.

  3. Have one of non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma and found torequire high-dose, melphalan-based chemotherapy and autologous stem cell transplant (ASCT) as part of standard of care treatment (includes patients receiving ASCT alsorequiring oxygen).

  4. Performance status of ECOG 0-2

  5. Are reliable and willing to make themselves available for the duration of the study,and are willing to follow study procedures.

Exclusion

Exclusion Criteria:

  1. Nasal blockage such as nasal polyps, deviated septum or nasal packing would eithernot allow the proper flow of heated humidity into the nares or it would be toouncomfortable to tolerate during the intervention.

  2. Those with influenza like illness. The intervention is not in itself, an aerosolgenerating medical device. However, if influenza positive, there could be airbornespread of the virus impacting both staff and other patients.

  3. Tracheostomy Tube Patients would require a different type of equipment attachmentwhich is not included in this study. Tracheostomy tubes by-pass the upper airway andtherefore the intervention cannot be used for the purpose of assessing mucositis.This intervention is used regularly on tracheostomy patients with good successhowever in this case, the upper airway is by-passed and therefore there would be noimpact on mucositis.

  4. Patients with significant co-morbidities that would prevent compliance of equipmentuse as determined by the treating physician.

  5. Patients who have Obstructive Sleep Apnea who use a CPAP machine at night. Thispopulation would not be able to use the intervention concurrently with the CPAPdevice as both utilize the nares.

Study Design

Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Airvo
Phase: 2
Study Start date:
November 05, 2024
Estimated Completion Date:
January 31, 2026

Study Description

This is a open label, case-control randomized, phase II clinical trial comparing the use of High Heated Humidity (H3) delivered using the Airvo 2 device to standard of care in Hematologic cancer recipients of autologous stem cell transplant (including Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma).

Mucositis and aerodigestive tract complications are common across most types of cytotoxic chemotherapies. These complications are both more frequent and severe in recipients of high dose chemotherapy (HDT) and autologous stem cell transplant (ASCT). By extending the use of H3 to include the HDT/ASCT population, there is the possibility to decrease or minimize the complications associated with the current standard treatment process. Shorter, less complicated hospital stays could results for those whose course would otherwise end up being longer due to complications/set- backs. The length of time to use the device per day is a minimum of 4 hours/day up to approximately 14 days while being an inpatient. Treatment beyond 14 days is exceptional and will be done only in those individuals who continue to have mucositis beyond 14 days. In this case, patients may receive treatment up to 30 days.

Connect with a study center

  • Cross Cancer Institute

    Edmonton, Alberta T6G 1Z2
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.